Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2034

Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2034

Key Highlights

DelveInsight’s analyst projects that among the total diagnosed prevalent cases of FSGS in 7MM approximately 202 thousand with 36% of cases were from the US.

According to the analysis conducted by DelveInsight’s, FSGS was diagnosed in approximately 60% males and 48% of females within the 7MM in 2022. This analysis indicates a higher prevalence of FSGS among males than females.

The highest proportion of FSGS cases was estimated in the 18-64 years age group in the 7MM, with an estimated 124 thousand cases, while the least cases were in the age group 0-17 years (18 thousand cases).

DelveInsight’s “Focal Segmental Glomerulosclerosis (FSGS) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of the FSGS, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Disease Understanding and Diagnosis Algorithm

Focal Segmental Glomerulosclerosis (FSGS) Overview

FSGS is a complex kidney disorder characterized by scarring in the glomeruli, the tiny blood vessels that filter waste and excess fluids from the blood, leading to proteinuria, edema, and often progressive renal dysfunction. While the exact causes are not fully understood, it is believed to involve genetic predispositions, immune system dysregulation, and various environmental factors. It presents a significant clinical challenge due to its heterogeneity in presentation and response to treatment.

Focal Segmental Glomerulosclerosis (FSGS) Diagnosis

The clinical diagnosis of FSGS is confirmed by electromyography (EMG) studies, pharmacologic testing, and serum Ab assay. Positive results on EMG confirm a postsynaptic defect of the NMT, the clinical response to cholinesterase inhibitors (ChE-Is) supports FSGS diagnosis, and detection of specific Abs confirms FSGS and identifies Ab-related subgroups. EMG confirmation is crucial in patients with neither AChR nor MuSK Abs on the standard assay. Diagnosing Focal Segmental Glomerulosclerosis (FSGS) is challenging due to its heterogeneous presentation and overlap with other renal diseases, compounded by limitations in renal biopsy and the risk of misdiagnosis. To address this, emerging non-invasive techniques like biomarkers (suPAR, podocyte-associated mRNA transcripts) and advanced imaging (MRI, PET) offer promise in differentiation and risk prediction.

Further details related to diagnosis are provided in the report…

Focal Segmental Glomerulosclerosis (FSGS) Epidemiology

As the market is derived using the patient-based model, the Focal Segmental Glomerulosclerosis (FSGS) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of FSGS, Gender-specific Diagnosed Prevalent Cases of FSGS, Age-specific Diagnosed Prevalent Cases of FSGS, and Comorbodity-specific Diagnosed Prevalent Cases of FSGS, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per DelveInsight’s estimations, the total diagnosed prevalent cases of FSGS in the 7MM were approximately 202 thousand in 2022 and are projected to increase during the forecast period.

The overall count of individuals diagnosed with FSGS in the United States was approximately 73 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).

Among the 7MM, EU4 and the UK accounted for nearly 102 thousand diagnosed prevalent cases of FSGS, and these cases are expected to increase during the forecast period (2023-2034).

Among EU4 and the UK, the UK had the highest diagnosed prevalent population of FSGS, with 26 thousand cases, followed by Germany and France in 2022. On the other hand, Italy had the lowest diagnosed prevalent population in EU4 and the UK in 2022.

In Japan, there were around 27 thousand diagnosed prevalent cases of FSGS in 2022. These cases are expected to increase at a significant CAGR.

The highest proportion of FSGS cases was estimated in the 18–64 years age group in the 7MM, while the least cases were in the age group <18 years.

Gender-specific diagnosed prevalent cases of FSGS showed that males were more affected by FSGS than females in the 7MM in 2022.

In the 7MM, type-specific cases were categorized into two groups: primary and secondary. The highest proportion of FSGS cases was estimated in the primary type, with nearly 163 thousand cases in 2022.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on FSGS evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL NYU Langone Medical Center, New York; Department of Internal Medicine, Jewish Hospital, US; University of Cologne, Cologne, Germany; Dipartimento di Neuroscienze, Unit of Nephrology and Dialysis, Department of Internal Medicine , Messina , Italy; Department of Nephrology, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain; Department of Pathology (Analytic Human Pathology), Nippon Medical School, Tokyo, Japan, and others.

Delveinsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of FSGS, explaining its causes, signs and symptoms, and pathogenesis.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

FSGS Report Insights

Patient Population

Country-wise Epidemiology Distribution

Diagnosed Prevalence of FSGS

Gender-specific Diagnosed Prevalence of FSGS

Age-specific Diagnosed Prevalence of FSGS

Severity-specific Diagnosed Prevalence of FSGS by MGFA classification

Antibody Serology of Generalized FSGS

FSGS Report Key Strengths

12 years Forecast

The 7MM Coverage

FSGS Epidemiology Segmentation

Key Questions

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of FSGS? What will be the growth opportunities across the 7MM concerning the patient population of FSGS?

What is the historical and forecasted FSGS patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

Why do only limited patients appear for diagnosis?

Which country is more prevalent for FSGS and why?

What factors are affecting the diagnosis of the indication?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the FSGS prevalence cases in varying geographies over the coming years.

A detailed overview of Severity, Gender, and Age-specific prevalence of FSGS.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The FSGS Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of FSGS cases in 2023?

The highest cases of FSGS was found in the UK among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of FSGS cases in 2023?

The highest cases of FSGS were found in the US among the 7MM in 2023.